JP2024527044A - ８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用 - Google Patents

８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用 Download PDF

Info

Publication number
JP2024527044A
JP2024527044A JP2024504951A JP2024504951A JP2024527044A JP 2024527044 A JP2024527044 A JP 2024527044A JP 2024504951 A JP2024504951 A JP 2024504951A JP 2024504951 A JP2024504951 A JP 2024504951A JP 2024527044 A JP2024527044 A JP 2024527044A
Authority
JP
Japan
Prior art keywords
mmol
alkyl
cancer
azabicyclo
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527044A5 (https=
JPWO2023005928A5 (https=
Inventor
チョン，ヤオバン
フアン，ヤーフェイ
ジョウ，ジュエン
ワン，ヨンフイ
ウェイ チェン，ワイアット
Original Assignee
エルアイティーティーディーディー メディシンズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルアイティーティーディーディー メディシンズ リミテッド filed Critical エルアイティーティーディーディー メディシンズ リミテッド
Publication of JP2024527044A publication Critical patent/JP2024527044A/ja
Publication of JP2024527044A5 publication Critical patent/JP2024527044A5/ja
Publication of JPWO2023005928A5 publication Critical patent/JPWO2023005928A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024504951A 2021-07-27 2022-07-26 ８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用 Pending JP2024527044A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110860428.3 2021-07-27
CN202110860428 2021-07-27
CN202210779302.8 2022-07-01
CN202210779302 2022-07-01
PCT/CN2022/107932 WO2023005928A1 (zh) 2021-07-27 2022-07-26 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途

Publications (3)

Publication Number Publication Date
JP2024527044A true JP2024527044A (ja) 2024-07-19
JP2024527044A5 JP2024527044A5 (https=) 2025-07-30
JPWO2023005928A5 JPWO2023005928A5 (https=) 2025-07-30

Family

ID=85060847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504951A Pending JP2024527044A (ja) 2021-07-27 2022-07-26 ８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用

Country Status (10)

Country Link
US (1) US20240294550A1 (https=)
EP (1) EP4378943A4 (https=)
JP (1) JP2024527044A (https=)
KR (1) KR20240041354A (https=)
CN (2) CN115677730B (https=)
AU (1) AU2022316931A1 (https=)
CA (1) CA3227713A1 (https=)
IL (1) IL310412A (https=)
TW (1) TW202321256A (https=)
WO (1) WO2023005928A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602891A (zh) * 2024-03-28 2026-01-16 大陸商勵締（杭州）醫藥科技有限公司 具有mTOR抑制活性的有機化合物及其用途
TW202545519A (zh) * 2024-05-15 2025-12-01 俄羅斯聯邦商拜奧卡德聯合股份公司 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑
WO2026037494A1 (en) * 2024-08-14 2026-02-19 Eracal Therapeutics Ltd. New compounds and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049017A1 (en) * 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020087170A1 (en) * 2018-10-30 2020-05-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2020259601A1 (en) * 2019-06-28 2020-12-30 Impact Therapeutics, Inc Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof
WO2021012049A1 (en) * 2019-07-22 2021-01-28 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
JP2023537055A (ja) * 2020-08-07 2023-08-30 アンテンジーン・ディスカバリー・リミテッド Ａｔｒ阻害剤およびその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
CN109071565B (zh) 2016-05-24 2022-05-10 默克专利股份公司 三环杂环衍生物
CN111848605B (zh) 2019-04-30 2023-05-02 四川科伦博泰生物医药股份有限公司 一种取代吡啶并[3,4-b]吡嗪-2(1H)-酮化合物、其制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020049017A1 (en) * 2018-09-07 2020-03-12 Merck Patent Gmbh 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020087170A1 (en) * 2018-10-30 2020-05-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
WO2020259601A1 (en) * 2019-06-28 2020-12-30 Impact Therapeutics, Inc Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof
WO2021012049A1 (en) * 2019-07-22 2021-01-28 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
JP2023537055A (ja) * 2020-08-07 2023-08-30 アンテンジーン・ディスカバリー・リミテッド Ａｔｒ阻害剤およびその使用

Also Published As

Publication number Publication date
WO2023005928A1 (zh) 2023-02-02
EP4378943A1 (en) 2024-06-05
TW202321256A (zh) 2023-06-01
EP4378943A4 (en) 2024-12-11
CA3227713A1 (en) 2023-02-02
AU2022316931A1 (en) 2024-03-14
CN115677730A (zh) 2023-02-03
US20240294550A1 (en) 2024-09-05
CN115677730B (zh) 2024-11-12
KR20240041354A (ko) 2024-03-29
IL310412A (en) 2024-03-01
CN118043325A (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
RU2622104C2 (ru) Макроциклические ингибиторы киназы lrrk2
JP2025532125A (ja) 新規なテトラヘテロサイクル化合物
JP2025523624A (ja) がんの治療のための方法
JP5555378B2 (ja) Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
JP2024527044A (ja) ８－オキソ－３－アザビシクロ［３．２．１］オクタン系化合物及びその塩、並びにその調製方法及び使用
JP2020511520A (ja) ピラゾロ［３，４−ｄ］ピリミジン−３−オンの大環状誘導体、その医薬組成物及び応用
JP7625141B2 (ja) Ｅｒｂｂ２の阻害剤としての縮合四環キナゾリン誘導体
CN112745335A (zh) 一种三并杂环化合物及其用途
TW202237597A (zh) 新型egfr降解劑
JP2023518609A (ja) 新規アミノピリミジン系ｅｇｆｒ阻害剤
CN113045559A (zh) 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
WO2021126923A1 (en) Cd206 modulators their use and methods for preparation
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
US20240383911A1 (en) Azaindazole macrocycle compounds and uses thereof
CN114478520A (zh) Bcl-2蛋白凋亡诱导剂及应用
CN116375712A (zh) 双吗啉取代的杂环化合物及其医药用途
CN120058702A (zh) 含杂环的tead抑制剂
TWI894448B (zh) Ctla-4小分子降解劑及其應用
JP7833477B2 (ja) 血管拡張性失調症変異（ａｔｍ）キナーゼの選択的モジュレーターおよびその使用
JPWO2023005928A5 (https=)
JP7335972B2 (ja) ピペラジンアミド誘導体、その製造方法及び医薬におけるその用途
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
HK40082693A (en) 8-oxo-3-azabicyclo[3.2.1]octane compounds or salts thereof, and preparation method and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319